Beijing Tiantan Biological Products Co., Ltd. logo

Beijing Tiantan Biological Products Co., Ltd. (600161)

Market Closed
10 Aug, 06:57
SSE SSE
¥
12. 78
+0.29
+2.3219%
¥
39.21B Market Cap
30.5 P/E Ratio
0.6% Div Yield
21.55M Volume
0 Eps
¥ 12.49
Previous Close
Add Transaction
Day Range
12.47 12.97
Year Range
11.12 20.77
Want to track 600161 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

600161 closed today higher at ¥12.78, an increase of 2.3219% from yesterday's close, completing a monthly increase of 10.3627% or ¥1.2. Over the past 12 months, 600161 stock lost -21.7391%.
600161 pays dividends to its shareholders, with the most recent payment made on Jul 24, 2026. The next estimated payment will be in In 11 months on Jul 24, 2027 for a total of ¥0.05.
The last earnings report, released on Apr 24, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.02%, based on the last three reports.
Beijing Tiantan Biological Products Co., Ltd. has completed 9 stock splits, with the recent split occurring on Jun 20, 2024.
The company's stock is traded on one exchange.

600161 Chart

People also search for

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.
¥ 139.77
+2.0293%
Shanghai United Imaging Healthcare Co., Ltd.
¥ 112.7
+0.1333%
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
¥ 30.46
-0.2293%
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. A Shares
¥ 137
+5.2874%
Shanghai Allist Pharmaceuticals Co., Ltd.
¥ 116.18
-0.6924%

Beijing Tiantan Biological Products Co., Ltd. (600161) FAQ

What is the stock price today?

The current price is ¥12.78.

On which exchange is it traded?

Beijing Tiantan Biological Products Co., Ltd. is listed on SSE.

What is its stock symbol?

The ticker symbol is 600161.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.6%.

What is its market cap?

As of today, the market cap is 39.21B.

Has Beijing Tiantan Biological Products Co., Ltd. ever had a stock split?

Beijing Tiantan Biological Products Co., Ltd. had 9 splits and the recent split was on Jun 20, 2024.

Beijing Tiantan Biological Products Co., Ltd. Profile

Biotechnology Industry
Healthcare Sector
Mr. Dao Xing Fu CEO
SSE Exchange
CNE000000WF9 ISIN
CN Country
4,858 Employees
24 Jul 2026 Last Dividend
22 Jun 2018 Last Split
18 May 1998 IPO Date

Overview

Beijing Tiantan Biological Products Co., Ltd. is a prominent player in the biopharmaceutical industry, primarily focused on the research and development, manufacture, sale, and consulting of blood products. Founded in 1919 and with its headquarters established in Beijing, China, this company has carved a niche for itself in the Chinese biopharmaceutical sector. As a subsidiary of China National Biotec Group Company Limited, Beijing Tiantan Biological Products operates under a considerable banner, contributing significant advancements and innovations in the field of biotechnology and pharmaceuticals, with a strong emphasis on products derived from human blood.

Products and Services

The company's portfolio encompasses a diverse range of blood-related products, tailored to meet a variety of medical needs. Their product lineup includes:

  • Human Albumin: A vital protein used in the treatment of shocks, burns, and low blood protein levels. It plays a crucial role in maintaining blood volume and pressure.
  • Intravenous Human Immunoglobulin: A therapy used for a range of immune deficiencies and autoimmune and inflammatory diseases, providing essential antibodies to patients with deficient or malfunctioning immune systems.
  • Tetanus Human Immunoglobulin: Specifically used for the prevention and treatment of tetanus, offering immediate immunity through the provision of tetanus antibodies.
  • Rabies Patient Immunoglobulin: Used as post-exposure prophylaxis against rabies infections, providing immediate but temporary antibodies to fight the virus following exposure.
  • Hepatitis B Human Immunoglobulin: Administered to prevent hepatitis B infection in individuals exposed to the virus, as well as in other specific medical situations like the newborns of mothers who are hepatitis B surface antigen positive.
  • Freeze-dried Intravenous Hepatitis B Human Immunoglobulin: A specialized formulation of hepatitis B immunoglobulin, designed for intravenous administration, offering convenience and improved stability.
  • Human Prothrombin Complex: This product is crucial for patients with clotting disorders, providing a concentrate of clotting factors to manage and prevent bleeding episodes.

Contact Information

Address: No.B2 Shuangqiao Road, Beijing, China, 100024
Phone: 86 10 6543 4018